However, our finding of APOBEC mutations in HR + HER2- subclonal mutations concurs with tissue biopsy sequencing studies12,15, and confirms that this process contributes to the subclonal diversity of HR + advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.